# US 2026/0285799 A1 · Polymorphic forms of (r)-oxybutynin hydrochloride

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0285799 A1
- Document ID: US20260285799A1
- Status: Published application
- Kind: A1
- Application number: 19/679,008
- Filed: 2026-05-15
- Published: 2026-09-24
- Earliest claimed: 2020-05-05
- Assignees: Apnimed, Inc. (Delaware)
- Applicants: Apnimed,Inc.(Delaware)
- Inventors: Dennis MOLNAR; Sean JOHNSTON
- Web page: https://patentgrep.com/patent/US20260285799A1

## CPC

- C07C 219/20: the carbon skeleton being unsaturated
- C07C 219/22: and containing six-membered aromatic rings
- A61P 11/00: Drugs for disorders of the respiratory system
- C07C 213/08: by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
- C07B 2200/07: Optical isomers
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Polymorphic forms of (R)-oxybutynin HCl, including three crystalline forms, are prepared and characterized. Uses of the various polymorphic forms of (R)-oxybutynin HCl for Obstructive Sleep Apnea (OSA) treatment are also disclosed.

## Claims

### Claim 1

A solid crystalline form of (R)-oxybutynin HCl, designated as Form C.

### Claim 2 (depends on 1)

The solid crystalline form of claim 1, having an X-ray powder diffraction pattern comprising at least three peaks, in terms of 2-theta, selected from the group consisting of 6.9 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 11.7 degrees 2θ±0.2 degree 2θ, 16.8 degrees 2θ±0.2 degree 2θ and 14.2 degrees 2θ±0.2 degree 2θ, at about ambient relative humidity.

### Claim 3 (depends on 1)

The solid crystalline form of claim 1, having an X-ray powder diffraction pattern comprising at least four peaks, in terms of 2-theta, selected from the group consisting of 6.9 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 11.7 degrees 2θ±0.2 degree 2θ, 16.8 degrees 2θ±0.2 degree 2θ, 14.2 degrees 2θ±0.2 degree 2θ, 7.6 degrees 2θ±0.2 degree 2θ, and 14.8 degrees 2θ±0.2 degree 2θ, at about ambient relative humidity.

### Claim 4 (depends on 1)

The solid crystalline form of claim 1, having an X-ray powder diffraction pattern comprising at least five peaks, in terms of 2-theta, selected from the group consisting of 6.9 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 11.7 degrees 2θ±0.2 degree 2θ, 16.8 degrees 2θ±0.2 degree 2θ, 14.2 degrees 2θ±0.2 degree 2θ, 7.6 degrees 2θ±0.2 degree 2θ, and 14.8 degrees 2θ±0.2 degree 2θ, 24.2 degrees 2θ±0.2 degree 2θ, 13.9 degrees 2θ±0.2 degree 2θ, and 8.7 degrees 2θ±0.2 degree 2θ, at about ambient relative humidity.

### Claim 5 (depends on 1)

The solid crystalline form of claim 1, having an X-ray powder diffraction pattern comprising at least seven peaks, in terms of 2-theta, selected from the group consisting of 6.9 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 11.7 degrees 2θ±0.2 degree 2θ, 16.8 degrees 2θ±0.2 degree 2θ, 14.2 degrees 2θ±0.2 degree 2θ, 7.6 degrees 2θ±0.2 degree 2θ, and 14.8 degrees 2θ±0.2 degree 2θ, 24.2 degrees 2θ±0.2 degree 2θ, 13.9 degrees 2θ±0.2 degree 2θ, and 8.7 degrees 2θ±0.2 degree 2θ, at about ambient relative humidity.

### Claim 6 (depends on 1)

The solid crystalline form of claim 1, having an X-ray powder diffraction pattern comprising the peaks, in terms of 2-theta, of 6.9 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 11.7 degrees 2θ±0.2 degree 2θ, 16.8 degrees 2θ±0.2 degree 2θ, 14.2 degrees 2θ±0.2 degree 2θ, 7.6 degrees 2θ±0.2 degree 2θ, and 14.8 degrees 2θ±0.2 degree 2θ, 24.2 degrees 2θ±0.2 degree 2θ, 13.9 degrees 2θ±0.2 degree 2θ, and 8.7 degrees 2θ±0.2 degree 2θ, at about ambient relative humidity.

### Claim 7 (depends on 1)

The solid crystalline form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 4 at about ambient relative humidity.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The solid crystalline form of any one of claims 1-7, having a differential scanning calorimetry (DSC) thermogram comprising a melting onset at 109.6° C. and an endothermic peak at 119.1° C.

### Claim 9 (depends on 8)

The solid crystalline form of claim 8, having a differential scanning calorimetry (DSC) thermogram substantially as shown in FIG. 7.

### Claim 10

A solid crystalline form of (R)-oxybutynin HCl, having a combination of the Form B and Form C polymorphs as shown in FIG. 9.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical composition comprising the solid crystalline form of any one of claims 1-9 and one or more pharmaceutically acceptable excipients.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A process for preparing the solid crystalline form of any one of claims 1-9, comprising precipitating the solid crystalline form from a solution comprising (R)-oxybutynin HCl and a solvent, or slurrying (R)-oxybutynin HCl in a solvent, wherein the solvent comprises an organic solvent excluding methanol, and the content of water is at or below 5% v/v.

### Claim 13 (depends on 12)

The process according to claim 12, wherein the organic solvent is selected from the group consisting of n-heptane, propyl acetate, ethyl acetate, isopropyl acetate, methyl isobutyl ketone (MIBK), methyl ethyl ketone (MEK), 1-propanol, ethanol, methyl t-butyl ether (MTBE), 1,4-dioxane, toluene, 1,2-dimethoxyethane, tetrahydrofuran, dichloromethane, acetonitrile, nitromethane, and mixtures thereof.

### Claim 14 (depends on 13)

The process of claim 13, wherein the organic solvent is MTBE.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method of treating a condition associated with pharyngeal airway collapse comprising administering to a subject in need thereof the solid crystalline form of any one of claims 1-9.

### Claim 16 (depends on 15)

The method of claim 15, wherein the condition associated with pharyngeal airway collapse is sleep apnea or snoring.

### Claim 17 (depends on 15)

The method of claim 15, wherein the condition associated with pharyngeal airway collapse is Obstructive Sleep Apnea (OSA).

### Claim 18

A solid crystalline form of (R)-oxybutynin HCl.

### Claim 19 (depends on 18)

The solid crystalline form of claim 18, which is Form A.

### Claim 20 (depends on 19)

The solid crystalline form of claim 19, having an X-ray powder diffraction pattern substantially as shown in FIG. 2 at about ambient relative humidity.

### Claim 21 (depends on 18)

The solid crystalline form of claim 18, which is Form B.

### Claim 22 (depends on 21)

The solid crystalline form of claim 21, having an X-ray powder diffraction pattern substantially as shown in FIG. 3 at about ambient relative humidity.

### Claim 23 (depends on 18, 19, 20, 21, 22)

A pharmaceutical composition comprising a solid crystalline form of (R)-oxybutynin HCl according to any one of claims 18-22 and optionally one or more pharmaceutically acceptable excipients.

### Claim 24

A solid crystalline form of (R)-oxybutynin citrate.

### Claim 25 (depends on 24)

A pharmaceutical composition comprising a solid crystalline form of (R)-oxybutynin citrate according to claim 24 and optionally one or more pharmaceutically acceptable excipients.

### Claim 26

A process for producing crystalline R-oxybutynin HCl of Form C, the process comprising:
isolating (R)-oxybutynin from racemic oxybutynin via chiral resolution with D-malic acid; and
adding HCl to the isolated (R)-oxybutynin to produce crystalline (R)-oxybutynin HCl of Form C.

### Claim 27 (depends on 26)

The process of claim 26, wherein isolating (R)-oxybutynin from racemic oxybutynin comprises adding D-malic acid to racemic oxybutynin free base.

### Claim 28 (depends on 27)

The process of claim 27, wherein D-malic acid is added to racemic oxybutynin free base in the presence of 2-propanol.

### Claim 29 (depends on 26)

The process of claim 26, wherein the HCl is added in the presence of ethyl acetate.

### Claim 30 (depends on 26)

The process of claim 26, further comprising adding MTBE to the isolated (R)-oxybutynin after addition of HCl.
